Shares of FibroGen, Inc (NASDAQ:FGEN) have been assigned a consensus rating of “Buy” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $66.60.

A number of research analysts have recently commented on FGEN shares. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research report on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Citigroup Inc. reaffirmed a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research report on Monday, June 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research report on Tuesday, August 8th. Finally, Stifel Nicolaus upped their price objective on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, August 8th.

Shares of FibroGen (FGEN) opened at 49.10 on Friday. The company’s market capitalization is $3.50 billion. FibroGen has a one year low of $15.60 and a one year high of $51.70. The company has a 50-day moving average price of $41.00 and a 200 day moving average price of $31.10.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. The firm had revenue of $29 million for the quarter, compared to the consensus estimate of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. On average, analysts forecast that FibroGen will post ($1.80) EPS for the current fiscal year.

In related news, Director Jorma Routti sold 12,000 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $47.36, for a total value of $568,320.00. Following the completion of the transaction, the director now owns 133,840 shares of the company’s stock, valued at $6,338,662.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Thomas B. Neff sold 38,636 shares of the stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $29.40, for a total transaction of $1,135,898.40. Following the completion of the transaction, the chief executive officer now directly owns 3,330,780 shares of the company’s stock, valued at approximately $97,924,932. The disclosure for this sale can be found here. Insiders have sold 498,338 shares of company stock valued at $19,420,269 in the last ninety days. 14.90% of the stock is owned by company insiders.

A number of large investors have recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 412 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in FibroGen by 1.7% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 29,090 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 474 shares in the last quarter. Principal Financial Group Inc. raised its position in FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after purchasing an additional 504 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in FibroGen by 15.4% in the second quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 696 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its position in FibroGen by 7.1% in the second quarter. Tudor Investment Corp ET AL now owns 12,095 shares of the biopharmaceutical company’s stock worth $391,000 after purchasing an additional 799 shares in the last quarter. 47.49% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/09/fibrogen-inc-fgen-receives-consensus-recommendation-of-buy-from-brokerages.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.